VARIAN MEDICAL SYSTEMS PARTICLE THERAPY GMBH & CO. KG

Their core work

Varian Medical Systems Particle Therapy GmbH & Co. KG is the German particle therapy division of Varian Medical Systems (acquired by Siemens Healthineers in 2021), based in Troisdorf and specializing in the design and delivery of proton beam therapy systems for cancer treatment. As an industry partner in EU research projects, they contribute commercial proton therapy technology, clinical infrastructure, and technical expertise to academic and hospital-led research consortia. Their involvement bridges the gap between research-grade radiobiology work and real-world clinical application, providing access to operational proton therapy equipment and the engineering knowledge that surrounds it. In practice, they serve as the industrial anchor in consortia that need both the physical systems and the applied know-how to conduct meaningful proton therapy research.

What they specialise in

How they've shifted over time

In the earlier period (INSPIRE, 2018-2022), Varian's H2020 involvement was centered on building and networking proton therapy research infrastructure — the keywords dosimetry, radiobiology, mathematical modeling, and patient selection databases all point to laying scientific groundwork and connecting research centers rather than generating clinical outcomes. By the more recent period (PROTECT-trial, 2021-2027), the focus has tightened sharply onto a single high-stakes clinical question: whether proton therapy outperforms conventional photon therapy for esophageal cancer. This shift from broad infrastructure-building to a targeted randomized clinical trial suggests Varian is moving toward generating clinical evidence that can justify wider adoption of proton therapy — which has direct commercial and regulatory implications for the company.

Varian is transitioning from supporting proton therapy's research ecosystem to generating the clinical trial evidence needed to establish proton therapy as a standard-of-care option — a trajectory that points toward more disease-specific and outcomes-focused collaborations in coming years.

How they like to work

Varian participates exclusively as a consortium partner, never as project coordinator, which is typical for large industrial companies that bring technology and infrastructure rather than project management capacity. Their two projects involved large, multi-country consortia (28 unique partners across 12 countries), suggesting they are comfortable operating within complex European research structures where their role is well-defined and specialized. This predictable industry-partner model makes them a reliable but not leadership-oriented collaborator — expect them to contribute equipment access, technical expertise, and clinical site support rather than driving scientific direction.

Varian has built connections with 28 unique consortium partners spanning 12 countries through just two projects, which is a notably broad reach for such a small project portfolio — a reflection of the large pan-European consortia that characterize proton therapy research networks. Their network is predominantly European, concentrated around countries with established particle therapy centres.

What sets them apart

Varian Particle Therapy Troisdorf is one of a very small number of commercial proton therapy system manufacturers present in the H2020 programme, giving them a near-unique position as a direct link between industrial particle therapy hardware and EU-funded clinical and radiobiology research. For a consortium building a proton therapy project, their participation can provide access to operational equipment, industry-grade dosimetry expertise, and commercially validated treatment planning knowledge that academic partners cannot offer. The Siemens Healthineers acquisition adds further weight — they sit at the intersection of one of the world's largest medical device ecosystems and a specialized particle therapy niche.

Highlights from their portfolio

• INSPIRE
  A large Research Infrastructure action (2018-2022) that networked proton therapy centres across Europe, with Varian as the industrial partner providing the commercial technology backbone — and the only project for which they received EC funding (EUR 204,071).
• PROTECT-trial
  A long-running (2021-2027) randomized clinical trial directly comparing proton and photon therapy for esophageal cancer, making it one of the most clinically consequential proton therapy trials in Europe and a direct validator of Varian's core technology.